PT  - JOURNAL ARTICLE
AU  - Guillaume Lamotte
AU  - Abhishek Lenka
TI  - Orthostatic Hypotension In Parkinson Disease: What Is New?
AID  - 10.1212/CPJ.0000000000200068
DP  - 2022 Aug 24
TA  - Neurology: Clinical Practice
PG  - 10.1212/CPJ.0000000000200068
4099  - http://cp.neurology.org/content/early/2022/08/24/CPJ.0000000000200068.short
4100  - http://cp.neurology.org/content/early/2022/08/24/CPJ.0000000000200068.full
AB  - Purpose of the review: Orthostatic hypotension (OH) is the primary manifestation of cardiovascular autonomic dysfunction in Parkinson’s disease (PD) and can be a prodromal feature of the disease. We review the recent progress in the field of autonomic dysfunction in PD.Recent findings: Individuals with isolated neurogenic OH should be followed up frequently as they may evolve into PD, dementia with Lewy bodies, or multiple system atrophy. The prevalence of OH in PD increases with disease stages but the role of levodopa remains unclear. Measurement of supine and standing heart rate and blood pressure allows for accurate identification of neurogenic OH in the clinic.Summary: Accurate identification of neurogenic OH in the clinic is crucial for identification of individuals who may benefit from participation in neuroprotective trials in the future. The treatment of OH in PD should be individualized and may reduce the risk of falls, cognitive impairment, and death.